"我们重构了能量循环新路径，通过创新设计葡萄糖回收与活化再利用机制，成功将理论淀粉得率 从50%提升至100%，从根本上解决了碳损耗问题。"张以恒介绍，同时，团队对酶元件稳定性进行了革 新，从特殊环境中系统挖掘并筛选出一系列具有优异热稳定性的新型酶元件，将整体反应温度提升至 50℃，不仅显著增强了酶活性与反应速率，还大幅降低了单位产出的酶用量，为工业化放大奠定了坚实 基础。团队还优化了系统集成，通过对反应体系中各因素的协同优化，最终将纤维素到淀粉的真实转化 率提升至93.3%。 值得一提的是，此项技术产出的淀粉为纯直链淀粉，聚合度高度可控，分子量分布（分散度）极 窄，结构均一性优于天然提取的淀粉，在食品、医药和材料领域展现出独特应用潜力。目前其已成功应 用于手性分离填料，高效分离沙利度胺等手性药物分子，突破了手性填料领域的技术瓶颈。 （原载于《科技日报》 2025-11-24 01版） 记者23日从中国科学院天津工业生物技术研究所获悉，该所体外合成生物学中心、低碳合成工程生 物学全国重点实验室张以恒研究员团队，在纤维素制淀粉领域取得重要进展。研究团队通过对合成技术 路径进行重构，实现了纤维素全碳素利用合成淀粉 ...

根据发行安排，本周(11月24日—11月28日)，A股市场将有两只新股申购，为科创板的摩尔线程和百奥 赛图，两股分别将于本周一和周五开启申购。 公司在国内GPU领域处于领先地位，基于自主研发的MUSA架构，公司率先实现了单芯片架构同时支持 AI计算加速、图形渲染、物理仿真和科学计算、超高清视频编解码的技术突破，有力推动了我国GPU 产业的自主可控进程。 2022—2024年，公司实现营业收入分别为0.46亿元、1.24亿元、4.38亿元，归属于母公司所有者的净利 润分别为-18.94亿元、-17.03亿元、-16.18亿元。 公司本次募集资金将投入摩尔线程新一代自主可控AI训推一体芯片研发项目、新一代自主可控图形芯 片研发项目、新一代自主可控AISoC芯片研发项目以及补充流动资金。 百奥赛图单一账户申购上限为7500股，顶格申购需持沪市市值7.5万元。 招股书显示，百奥赛图是一家临床前CRO以及生物技术企业。公司基于自主开发的基因编辑技术提供 各类创新模式动物以及临床前阶段的医药研发服务，并利用其自主开发的RenMice全人抗体小鼠平台(包 括RenMab、RenLite、RenNano、RenTCR以及Re ...

（文章来源：科技日报） 近年来，通过"纤维素部分水解—纤维二糖磷解—葡萄糖聚合淀粉"的多酶级联策略，体外生物转化技术 已能实现纤维素向淀粉的部分转化。但受限于合成路线，理论产率只有50%，且需依赖微生物发酵辅 助，实际产率更低，难以满足工业化需求。 "我们重构了能量循环新路径，通过创新设计葡萄糖回收与活化再利用机制，成功将理论淀粉得率从 50%提升至100%，从根本上解决了碳损耗问题。"张以恒介绍，同时，团队对酶元件稳定性进行了革 新，从特殊环境中系统挖掘并筛选出一系列具有优异热稳定性的新型酶元件，将整体反应温度提升至 50℃，不仅显著增强了酶活性与反应速率，还大幅降低了单位产出的酶用量，为工业化放大奠定了坚实 基础。团队还优化了系统集成，通过对反应体系中各因素的协同优化，最终将纤维素到淀粉的真实转化 率提升至93.3%。 记者23日从中国科学院天津工业生物技术研究所获悉，该所体外合成生物学中心、低碳合成工程生物学 全国重点实验室张以恒研究员团队，在纤维素制淀粉领域取得重要进展。研究团队通过对合成技术路径 进行重构，实现了纤维素全碳素利用合成淀粉。相关研究成果近日发表在《国家科学评论》期刊上。 值得一提的是， ...

根据发行安排，本周（11月24日—11月28日），A股市场将有两只新股申购，为科创板的摩尔线程和百 奥赛图，两股分别将于本周一和周五开启申购。 资料显示，摩尔线程是国内GPU领域龙头，公司是国内极少数具备全功能GPU研发能力的企业，上市后 公司将成为"国产GPU第一股"。百奥赛图是全球领先的创新技术驱动型生物技术公司。 炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 原标题：年内第一高价新股，今日申购！ 百奥赛图单一账户申购上限为7500股，顶格申购需持沪市市值7.5万元。 招股书显示，百奥赛图是一家临床前CRO以及生物技术企业。公司基于自主开发的基因编辑技术提供 各类创新模式动物以及临床前阶段的医药研发服务，并利用其自主开发的RenMice全人抗体小鼠平台 （包括RenMab、RenLite、RenNano、RenTCR以及RenTCR-mimic多个系列）针对人体内近千个潜在药 物靶点进行规模化药物发现与开发（以下简称"千鼠万抗"），并将有潜力的抗体分子对外转让、授权或 合作开发。经过十余年的积淀，公司逐步发展为以基因编辑模式动物制备、创新模式动物繁殖与供应、 临床前药理药效评价 ...

根据发行安排，本周（11月24日—11月28日），A股市场将有两只新股申购，为科创板的摩尔线程和百奥赛图， 两股分别将于本周一和周五开启申购。 资料显示，摩尔线程是国内GPU领域龙头，公司是国内极少数具备全功能GPU研发能力的企业，上市后公司将 成为"国产GPU第一股"。百奥赛图是全球领先的创新技术驱动型生物技术公司。 依托于抗体药物发现平台的领先优势，公司通过RenMice小鼠授权以及"千鼠万抗"的形式展开抗体对外合作开 发。目前公司已与Merck KGaA（德国默克）、Gilead Sciences（吉利德科学）、Johnson&Johnson（强生公 司）、IDEAYA Biosciences、Neurocrine Biosciences、百济神州、Xencor、ADC Therapeutics、Myricx Bio、 ABL Bio、翰森制药、正大天晴、华润生物、信达生物、荣昌生物、上海生物制品研究所等数十家海内外知名 生物科技或医药研发企业就"千鼠万抗"发现的药物分子授权/转让或RenMice平台授权达成合作。 2022—2024年，公司实现营业收入分别为5.34亿元、7.17亿元、9.8亿元，归属 ...

根据目前的发行安排，下周有2只新股申购，均为科创板新股。 从日程安排看，下周一（11月24日）可申购摩尔线程，下周五（11月28日）可申购百奥赛图。 | | 下周新股申购安排 | | | | | --- | --- | --- | --- | --- | | 日期 | 新股 | 发行价/股 | 发行市盈率 | 上市板 | | 周一 (11月24日) | 摩尔线程 (申购代码: 787795) | 114.28元 | | 科创板 | | 周五 (11月28日) | 百奥赛图 (申购代码: 787796) | 待定 | | 科创板 | 摩尔线程是国产GPU龙头，上市后将成为"国产GPU第一股"。 百奥赛图本次公开发行股票数量为4750万股，网上发行申购上限为7500股，顶格申购需配沪市市值7.5万元。 招股书显示，百奥赛图成立于2009年，是一家专注于临床前研究的CRO及生物技术公司。公司依托自主基因编辑技术，提供各类创新模式动物和临 床前医药研发服务，并利用其RenMice全人抗体/TCR小鼠平台，开展"千鼠万抗"计划，规模化发现和开发抗体药物分子，通过对外授权或合作开发 实现价值转化。2022年，百奥赛图在港 ...

(1)公司是否存在股权代持，包括历史沿革及现有股东间接持有发行人的股份中是否存在股权代持情 形，不限于直接持股股东； (2)发行人顾问邵文姬配偶的基本信息及顾问合同期限； (3)公司员工持股计划包括少量外部人员，请补充说明相关人员的入股价格、作价依据、价格公允性、 资金来源，如入股价格与员工相同或相近，应当说明是否存在利益输送，并出具明确的结论性意见。 11月21日，中国证监会公布境外发行上市备案补充材料要求公示(2025年11月17日—2025年11月21日)。 证监会要求麦科奥特补充说明历次增资及股权转让价格、定价依据及公允性，是否实缴出资，是否存在 未履行出资义务、抽逃出资、出资方式存在瑕疵的情形；就公司设立及历次股权变动是否合法合规进行 核查，并出具结论性意见。据港交所9月29日披露，麦科奥特向港交所提交上市申请书，建银国际、招 商证券国际为其联席保荐人。该公司有望成为多肽创新药第一股。 同时，证监会要求公司补充说明以下事项，请律师核查并出具明确的法律意见： 按照《监管规则适用指引——境外发行上市类第2号》补充说明公司控股股东及主要股东上层投资人西 安众瑞泽康企业管理咨询有限公司、Nexarcana ...

Core Viewpoint - Public QDII funds are leveraging their positions in the US stock market to enhance net value defense and differentiate their product offerings amidst the recent pullback in the Hong Kong stock market [1][2]. Group 1: Performance of QDII Funds - Despite an overall decline in net value for public QDII funds in recent months, those with a focus on US stocks have shown strong performance, ranking among the top in net value gains during market adjustments [2][4]. - Notable QDII funds such as CICC Global Healthcare and E Fund Global Growth Select have reported significant gains of 11.78% and 7.22% respectively over the past month, making them some of the few active equity QDIIs to achieve positive returns [2]. Group 2: Stock Selection and Market Strategy - Core stocks from the US market have bolstered the net value defense of these funds, with examples like Cidara, which saw a 105% increase in a single day due to a major acquisition announcement [3]. - The strategy of reallocating from Hong Kong stocks to US stocks has been evident, with some funds increasing their US stock positions significantly, such as CICC Global Healthcare, which shifted from 3% to 71% in US stocks within a quarter [6]. Group 3: Differentiation and Market Trends - The trend of increasing US stock positions among public QDIIs has been apparent since the end of Q3, as funds seek to distinguish themselves in a competitive market [4][5]. - The E Fund Asia Select QDII, managed by a prominent fund manager, has benefited from a 40% annual return, attributed to a 32.24% allocation in US stocks, significantly higher than earlier in the year [5]. Group 4: Impact of AI and Technology - The demand for computing power driven by AI technology has significantly enhanced the attractiveness of US QDIIs, with fund managers optimistic about the long-term investment value in leading tech companies [7][8]. - The rapid growth in AI applications has led to increased expectations for the scale of computing infrastructure, with funds like Jianxin Emerging Markets QDII holding 50% in US stocks, reflecting a strategic focus on this sector [8].

Core Viewpoint - The article highlights the importance of supporting rural children's growth and education, showcasing the "Youyi New Bud" Sunshine Care Program by Jiabiou Biotechnology, which aims to provide safety and support for students in rural areas [1][2]. Group 1: Company Initiatives - Jiabiou Biotechnology has launched the "Youyi New Bud" Sunshine Care Program, collaborating with various partners to provide tailored safety uniforms and winter pants to 189 students at a primary school in Laifeng County [1][2]. - The program follows a mature public welfare model of "material donation + knowledge transfer," emphasizing both material support and educational empowerment for rural children [1][2]. Group 2: Community Impact - The donated "Siyuan Ark" safety uniforms are designed with reflective strips to enhance visibility in low-light conditions, increasing the distance at which drivers can see students to over 150 meters [2]. - The initiative reflects a collaborative effort among local organizations, including the Laifeng County Golden Sun Public Welfare Association, to innovate public welfare models and support rural education [2][3]. Group 3: Future Directions - Laifeng County plans to continue fostering public welfare cooperation platforms to channel quality resources into rural education and child care [3]. - Jiabiou Biotechnology aims to deepen its commitment to public welfare while maintaining its focus on its core biotechnology business, demonstrating corporate social responsibility [3].

Summary of RenovoRx Conference Call (November 20, 2025) Company Overview - **Company**: RenovoRx (NasdaqCM:RNXT) - **Market Cap**: Approximately $30 million - **Focus**: Interventional oncology with a late-stage product in development and a commercial catheter device - **Current Stock Price**: Approximately $0.75 - **Analyst Rating**: Buy rating with a price target of $3 per share [1][17] Core Business and Product Development - **Product**: RenovoCath, a catheter device for localized chemotherapy - **Revenue**: Achieved $900,000 in revenue through Q3 2025 without a dedicated sales and marketing team [3][13] - **Market Potential**: Estimated peak sales potential for the catheter is about $400 million [3][8] - **Commercialization Strategy**: Initiated in early 2025, focusing on understanding market dynamics and barriers to adoption [3][9] Technology and Treatment Approach - **Innovative System**: Developed a new treatment method called TransArterial Microperfusion (TAMP) for localized chemotherapy [2][5] - **Mechanism of Action**: Allows for a hundred-fold increase in tissue concentration of chemotherapy compared to systemic delivery [7][8] - **Targeted Conditions**: Primarily focused on locally advanced pancreatic cancer, with ongoing phase III trials [4][10] Clinical Trials and Efficacy - **Phase III Trial**: Enrollment expected to complete early next year, with final data anticipated in 2027 [4][14] - **Survival Benefits**: Interim analysis shows a six-month survival benefit, with patients living approximately 21.5 months compared to 15.5 months in the control group [10][40] - **Quality of Life**: Notable 65% reduction in systemic toxicities and adverse events compared to traditional therapies [11][40] Market Dynamics and Sales Strategy - **Target Market**: Approximately 200 hospitals in the U.S. with specialized cancer centers [9] - **Sales Force**: Currently expanding with the hiring of a Senior Director of Sales and Marketing, along with additional sales representatives [9][20] - **Revenue Model**: Each patient may require multiple procedures, potentially generating $50,000 to $100,000 in revenue per patient [19][22] Financial Overview - **Cash Position**: $10 million in cash as of Q3 2025, with a monthly burn rate of $800,000 [16][44] - **Profitability Outlook**: Positive contribution margin on the device, with a goal to reach break-even with 25-50 hospitals actively using the device [22][23] Future Prospects and Strategic Initiatives - **Post-Marketing Registry Study**: Launched to track data on the use of RenovoCath across various cancers [12][13] - **Expansion Plans**: Exploring additional indications and potential partnerships with other biotech firms for drug-device combinations [42][43] - **Regulatory Strategy**: Aiming for a J-code drug reimbursement for the drug-device combination, which could significantly increase market potential [17] Key Takeaways - RenovoRx is positioned to disrupt traditional cancer treatment paradigms with its innovative localized chemotherapy approach - The company is on track to expand its market presence and revenue generation capabilities through strategic hiring and commercialization efforts - Clinical trial results and a strong focus on quality of life improvements are expected to drive adoption among oncologists and patients alike [10][11][40]